Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to “Buy” at StockNews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Sunday.

Separately, TheStreet cut shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Thursday, February 8th.

Vanda Pharmaceuticals Trading Down 1.5 %

NASDAQ VNDA opened at $4.06 on Friday. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $7.00. The company has a market capitalization of $233.61 million, a PE ratio of 81.22 and a beta of 0.76. The stock has a 50-day simple moving average of $4.15 and a 200 day simple moving average of $4.05.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The company had revenue of $45.27 million during the quarter, compared to analysts’ expectations of $37.00 million. As a group, sell-side analysts predict that Vanda Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of VNDA. Envestnet Asset Management Inc. increased its stake in Vanda Pharmaceuticals by 11.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 11,210 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,146 shares during the last quarter. Yousif Capital Management LLC raised its stake in shares of Vanda Pharmaceuticals by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company’s stock worth $574,000 after purchasing an additional 1,180 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Vanda Pharmaceuticals by 0.9% in the 2nd quarter. Legal & General Group Plc now owns 134,874 shares of the biopharmaceutical company’s stock valued at $1,471,000 after buying an additional 1,223 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Vanda Pharmaceuticals by 91.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,538 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 2,644 shares in the last quarter. Finally, CWM LLC increased its holdings in Vanda Pharmaceuticals by 61.1% during the third quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 2,732 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.